So I'm trying to speculate the next move here for
Post# of 5066
Posted On: 12/19/2015 3:49:53 PM
So I'm trying to speculate the next move here for BMSN. They are at over 4billion outstanding and have 8 billion Authorized. So they still have over 3billion shares to use. So I don't see a R/S happening...yet. Will it happen? If not, then the only simple possibilities for a significant increase in price would be moving out of this fuzzy valuation of Regen's current pipeline products or a share buy back. Both of which will not happen until human efficacy past phase 1 (will take some of the fuzz away) or a partnership/buyout at or past phase 2.
Regen is likely far from selling HemaXellerate. They probably are waiting for orphan and phase trials also adding multiple other indications to this therapy to increase its value.
Then there is dCellVax, and the NR2F6 trains moving full speed right behind HemaXellerate. As well as the coveted BORIS ip. Sprinkled generously also with other technology patents and ip on deck.
As Christopher Mizer (former CFO) stated, they were not looking for capital in the beginning, but for quality partnerships. It seems this has occurred and, fortunately, seems to be continuing to evolve as company succeeds to move the pipeline into clinics. In hindsight, it seems it was Koos's plan to use shares and spin offs to advance much of the business model.
Good news is it seems this part of the financial model has also evolved as stated in the PR introducing the NEW CFO Lander. Regen's expectation of Mr. Lander is to secure NON-DILUTIVE FINANCING.
So how will the remaining 3+ billion BMSN common shares be spent? At .0003 I doubt we will see dilution...now.
But what is the market value of orphan designated treatment of non synthetic cytocine treatment for bone marrow that also contains stem cells to modulate the immune system and .... Well you all have read what hemaXellerate can do.
My thought goes to considering the fully diluted value of BMSN.
Then it goes to the possibility (down the road within a few months) Of a PR on financing and one that gives investors that "less fuzzy" idea of what just HemaXellerate itself is valued at. (THIS NOT INCLUDING OTHER IP)
So even fully diluted, BMSN w/ its orphan designated HemaXellerate I, could be at .04 - .05. !
So I am reassured by the near doubling of the A/S here as it signaled their confidence in open IND and perhaps in the success of trials in the US (there could be trials now outside the us or in the works).
So if there were to be a reverse split, I confidently do not see it happening for almost a year or longer. It may stay at this level until there are crystallizing events pointing at actual product value. Also this may point to new investors as position building opportunities.
I've gone on to long here. This is far from done in my opinion! And all of this is in my opinion of course. Interested in folks with other thoughts on BMSN specifically here.
Have a great weekend all. Thanks for reading
Regen is likely far from selling HemaXellerate. They probably are waiting for orphan and phase trials also adding multiple other indications to this therapy to increase its value.
Then there is dCellVax, and the NR2F6 trains moving full speed right behind HemaXellerate. As well as the coveted BORIS ip. Sprinkled generously also with other technology patents and ip on deck.
As Christopher Mizer (former CFO) stated, they were not looking for capital in the beginning, but for quality partnerships. It seems this has occurred and, fortunately, seems to be continuing to evolve as company succeeds to move the pipeline into clinics. In hindsight, it seems it was Koos's plan to use shares and spin offs to advance much of the business model.
Good news is it seems this part of the financial model has also evolved as stated in the PR introducing the NEW CFO Lander. Regen's expectation of Mr. Lander is to secure NON-DILUTIVE FINANCING.
So how will the remaining 3+ billion BMSN common shares be spent? At .0003 I doubt we will see dilution...now.
But what is the market value of orphan designated treatment of non synthetic cytocine treatment for bone marrow that also contains stem cells to modulate the immune system and .... Well you all have read what hemaXellerate can do.
My thought goes to considering the fully diluted value of BMSN.
Then it goes to the possibility (down the road within a few months) Of a PR on financing and one that gives investors that "less fuzzy" idea of what just HemaXellerate itself is valued at. (THIS NOT INCLUDING OTHER IP)
So even fully diluted, BMSN w/ its orphan designated HemaXellerate I, could be at .04 - .05. !
So I am reassured by the near doubling of the A/S here as it signaled their confidence in open IND and perhaps in the success of trials in the US (there could be trials now outside the us or in the works).
So if there were to be a reverse split, I confidently do not see it happening for almost a year or longer. It may stay at this level until there are crystallizing events pointing at actual product value. Also this may point to new investors as position building opportunities.
I've gone on to long here. This is far from done in my opinion! And all of this is in my opinion of course. Interested in folks with other thoughts on BMSN specifically here.
Have a great weekend all. Thanks for reading
(1)
(0)